US FDA approves Stallergenes' allergy tablet Oralair

The US Food and Drug Administration has approved Oralair immunotherapy tablet from French allergen specialist Stallergenes (Euronext Paris: GENP) for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis.

Until now, allergen immunotherapy has been administered via a series of subcutaneous injections in the allergy specialist’s office. The approval of Oralair provides an additional treatment option for allergy specialists and their patients. Grass allergy is the most common seasonal allergy in the USA and most people are allergic to more than one type of grass. Oralair contains a mix of five grass pollens: Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass. The five grass pollens contained in Oralair represent those to which most patients in the US are exposed.

Christian Chavy, newly appointed chief executive of Stallergenes, said: “We are very pleased with the US approval of Oralair as it will bring a true benefit to US patients suffering from grass pollen-induced allergy. This approval is a major milestone for Stallergenes. The company not only developed Oralair but it also continues to expand the frontiers of allergen immunotherapy.”